Literature DB >> 26248153

Review of Commonly Used Serum Tumor Markers and Their Relevance for Image Interpretation.

Michael J Reiter1, Justin E Costello, Ryan B Schwope, Christopher J Lisanti, Michael B Osswald.   

Abstract

Serum tumor markers are firmly entrenched as one of the primary tools in an oncologist's armamentarium. They can be implemented in a broad range of applications from diagnostic assistance, assessing prognosis, or guiding therapeutic decisions. However, tumor markers also have limitations, which significantly impact how they should be used. Radiologists should be familiar with the following most prevalent tumor markers, which will all be discussed here: prostate-specific antigen (prostate), carcinoembryonic antigen (colon), α-fetoprotein (hepatocellular and testicular), carbohydrate antigen 19.9 (pancreas), cancer antigen 125 (ovarian), human chorionic gonadotropin/lactic dehydrogenase (testicular), and chromogranin A (neuroendocrine). This knowledge should avoid needless intervention, enhance image interpretation, and ultimately provide optimal patient care.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26248153     DOI: 10.1097/RCT.0000000000000297

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  6 in total

1.  Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.

Authors:  Le Shi; Fan Yang; Fei Luo; Yi Liu; Feng Zhang; Meijuan Zou; Qizhan Liu
Journal:  Tumour Biol       Date:  2016-07-23

2.  CA125 is a potential biomarker to predict surgically incurable gastric and cardia cancer: A retrospective study.

Authors:  Taobo Luo; Wenhu Chen; Lifang Wang; Hongguang Zhao
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

3.  Pituitary sex hormones enhance the pro‑metastatic potential of human lung cancer cells by downregulating the intracellular expression of heme oxygenase‑1.

Authors:  Ahmed Abdelbaset-Ismail; Daniel Pedziwiatr; Gabriela Schneider; Jacek Niklinski; Radoslaw Charkiewicz; Marcin Moniuszko; Magda Kucia; Mariusz Z Ratajczak
Journal:  Int J Oncol       Date:  2016-12-02       Impact factor: 5.650

4.  Is Awareness Enough to Bring Patients to Colorectal Screening?

Authors:  Márton István Dénes; Valentin Nădășan; Călin Molnar; Șerban Bancu; Cristian Oliviu Borz; Zoltán Ábrám
Journal:  Open Med (Wars)       Date:  2018-11-25

5.  Screening Circulating Tumor Cells as a Noninvasive Cancer Test in 3388 Individuals from High-Risk Groups (ICELLATE2).

Authors:  Juan Castro; Luis Sanchez; María Teresa Nuñez; Ming Lu; Tomas Castro; Hamid R Sharifi; Christer Ericsson
Journal:  Dis Markers       Date:  2018-05-28       Impact factor: 3.434

6.  Dynamic monitoring of serum specific tumor markers predicts the response to PD-1 blockade and prognosis of patients with malignant tumors.

Authors:  Qian Dong; Xin Sun; Yang Zhou; Yan-Wen Diao; Jia-Ling Ran; Jing-Dong Zhang
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.